Tag : GEMCITABINE

The phase 2 SAKK 06/19 study demonstrated that adding intravesical recombinant BCG (rBCG) to perioperative cisplatin/gemcitabine + atezolizumab achieved a high pathological complete response (pCR) rate in patients with muscle-invasive bladder cancer (MIBC) while maintaining a feasible and tolerable safety profile, supporting further evaluation of this multimodal strategy in randomized clinical trials.

Biliary tract cancer accounts for 10%-15% of all primary liver cancers in adults and includes tumors of the gallbladder and biliary tree. BTC is less common in Western populations but occurs more frequently in Asia. Notably, the incidence of intrahepatic cholangiocarcinoma has been rising worldwide, driven in part by metabolic disorders such as obesity, diabetes, and liver cirrhosis.